Wim A. van der Steeg, M.D.; Christopher P. Cannon, M.D., F.A.C.C. As extensively discussed in literature, this unexpected outcome is hypothesized to relate to the ...

Fasting serum concentrations of total cholesterol, triglycerides, HDL-cholesterol (HDL-C), HDL2-cholesterol (HDL2-C), HDL3-cholesterol (HDL3-C), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), ...

As with other disease states, biomarkers that can provide value across diagnosis, prognosis, and treatment response, have ...

Muvalaplin reduces lipoprotein(a) levels, according to a study published online Nov. 20 in the Journal of the American ...

Muvalaplin significantly lowered lipoprotein(a) levels, reducing the risk of cardiovascular events in high-risk adults.

Forty-four patients had genetically confirmed FCS and 31 patients had clinically diagnosed FCS. Plozasiran, at the 25 mg dose being proposed for marketing approval, induced rapid, deep, and sustained ...

Eisai serves as the lead for lecanemab's development and regulatory submissions globally with both Eisai and Biogen ...